|
Report No. : |
347165 |
|
Report Date : |
30.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
TOTAL PHARMA CORPORATION LIMITADA |
|
|
|
|
Registered Office : |
Bufete Facio Y Canas, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
Not Available |
|
|
|
|
Legal Form : |
International Business Company |
|
|
|
|
Line of Business : |
Limited Company |
|
|
|
|
No. of Employees : |
5 Employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Maximum Credit Limit : |
USD 60 000 |
|
|
|
|
Status : |
Offshore Company |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Costa Rica |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
COSTA RICA - ECONOMIC OVERVIEW
Prior to the global economic crisis, Costa Rica enjoyed stable economic growth. The economy contracted 1.3% in 2009 but resumed growth at about 4% per year in 2010-14. While the traditional agricultural exports of bananas, coffee, sugar, and beef are still the backbone of commodity export trade, a variety of industrial and specialized agricultural products have broadened export trade in recent years. High value-added goods and services, including medical devices, have further bolstered exports. Tourism continues to bring in foreign exchange, as Costa Rica's impressive biodiversity makes it a key destination for ecotourism. Foreign investors remain attracted by the country's political stability and relatively high education levels, as well as the incentives offered in the free-trade zones; and Costa Rica has attracted one of the highest levels of foreign direct investment per capita in Latin America. However, poor infrastructure, high energy costs, bureaucracy, weak investor protection, and legal uncertainty due to difficulty of enforcing contracts and overlapping and at times conflicting responsibilities between agencies, remain impediments to greater competitiveness. Costa Rica’s economy also faces challenges due to a rising fiscal deficit, rising public debt, and relatively low levels of domestic revenue. Poverty has remained around 20-25% for nearly 20 years, and the strong social safety net that had been put into place by the government has eroded due to increased financial constraints on government expenditures. Unlike the rest of Central America, Costa Rica is not highly dependent on remittances, which in 2013 represented 1.1% of GDP. Immigration from Nicaragua has increasingly become a concern for the government.
The estimated 300,000-500,000 Nicaraguans in Costa Rica, legally and illegally, are an important source of mostly unskilled labor, but also place heavy demands on the social welfare system. The US-Central American-Dominican Republic Free Trade Agreement (CAFTA-DR) entered into force on 1 January 2009 after significant delays within the Costa Rican legislature. CAFTA-DR has increased foreign direct investment in key sectors of the economy, including the insurance and telecommunications sectors recently opened to private investors.
|
Source
: CIA |
STATUTORY INFORMATION
|
|
|
Order: |
Total Pharma Corporation Ltda |
|
Address in the order: |
San Francisco de Guadalupe, Barrio Toumon, Oficinas de facio y Canas
Cedula Juridica 3-102-424614, San Jose- Costa Rica |
|
Legal Name: |
TOTAL PHARMA CORPORATION LIMITADA |
|
Trade Name: |
TOTAL PHARMA CORPORATION |
|
Cédula Jurídica: |
3-102-424614 |
|
Date Created: |
NA |
|
Date Incorporated: |
NA |
|
Legal Address: |
Bufete Facio Y Canas |
|
Operative Address: |
Bufete Facio Y Canas |
|
Telephone: |
2256 5555 |
|
Fax: |
2255 2510 |
|
Legal Form: |
Limited Company |
|
Email: |
|
|
Registered in: |
Costa Rica |
|
Website: |
|
|
Contact: |
Edwin Mora Murcia, General Manager |
|
Staff: |
5 |
|
Activity: |
International Business Company |
|
|
|
|
|
|
BANKS
|
|
|
Banco Central de Costa Rica |
|
|
The company does not disclose its banking details |
|
|
|
|
|
|
|
History
|
|
|
We could not confirm experience of the company. |
|
|
|
|
|
|
|
PRINCIPAL ACTIVITY
|
|
|
|
TOTAL PHARMA CORPORATION LIMITADA is an International Business Company
incorporated in Costa Rica for tax purposes. |
|
Products/Services description: |
Pharmaceutical Products |
|
Brands: |
NA |
|
Sales are: |
Wholesale |
|
Clients: |
TERBOL SA |
|
Suppliers: |
PRODUCTORES DE ENVASES FARMACEUTICOS S A S PROENFAR S A S |
|
Operations area: |
National and International |
|
The company imports from |
India, Colombia |
|
The company exports to |
Bolivia |
|
The subject employs |
5 Employees |
|
Payments: |
Unknown |
|
|
|
|
|
|
LOCATION
|
|
|
Headquarters : |
Bufete Facio Y Canas |
|
Branches: |
NA |
|
|
|
|
|
|
GROUP STRUCTURE AND
SUBSIDIARY COMPANIES
|
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders: |
This is a private company. We could not confirm shareholders. |
|
Management: |
Fernan Pacheco Alfaro, Legal Representative |
|
|
|
|
|
|
FINANCIAL INFORMATION
|
|
|
This is a private company which does not make its financial public. |
|
|
|
|
|
|
|
USD 2014
|
|
|
Revenue |
2 700 000 |
|
Cash Flow |
Normal |
|
|
|
|
|
|
LEGAL FILINGS
|
|
|
There are no legal connected to the subject |
|
|
|
|
|
|
|
REVIEW
|
|
|
Requested Credit Amount |
Maximum |
|
Maximum Credit Provided |
USD 60 000 |
|
|
|
|
|
|
SUMMARY
|
|
|
This is an International Business Company which does not belong to a
company located in Costa Rica. |
|
|
|
|
|
|
|
RISK INFORMATION
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
Unknown |
|
CASH FLOW |
Normal |
|
SUGGESTED CREDIT LINE |
USD 60 000 |
|
STATUS |
This Corporation is in Good Standing |
|
|
|
|
|
|
INTERVIEW
|
|
|
NAME |
NA |
|
POSITION |
Agent |
|
COMMENTS |
He confirmed they are the agents in charge of the company. However,
they refused to confirm data. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.15 |
|
|
1 |
Rs.99.36 |
|
Euro |
1 |
Rs.71.25 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAS |
|
|
|
|
Report Prepared by
: |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.